Program - International Immunocompromised Host Society

Welcome to the ICHS14 in Berlin
Final Program
18th Symposium
on Infections in the
Immunocompromised Host
15 – 17 June 2014
Berlin, Germany
Langenbeck-Virchow-Haus
Local chair:
Georg Maschmeyer
Potsdam, Germany
www.ichs.org
1
Welcome to the ICHS14 in Berlin
bei invasiven Aspergillosen
1)
Vertrauen Sie dem Goldstandard*
➜ AI-Empfehlung bei invasiver Aspergillose
in AGIHO2,3-, ECIL4 -, IDSA5-Guidelines
➜ Verbesserte Überlebensraten6
➜ Höhere Wirksamkeit 6
VFEND® 50 mg, 200 mg Filmtabletten. VFEND® 200 mg Pulver zur Herstellung einer Infusionslösung. VFEND® 40 mg/ml Pulver zur Herstellung einer Suspension zum Einnehmen. Wirkstoff: Voriconazol. Zusammensetzung:
Wirkstoff: Filmtabletten: 1 Filmtablette enthält 50 mg/200 mg Voriconazol. Pulver (Infusionslösung): 1 ml enthält nach Rekonstitution 10 mg Voriconazol. Nach der Rekonstitution ist eine weitere Verdünnung nötig, bevor
appliziert werden kann. 1 Durchstechflasche enthält 200 mg Voriconazol. Pulver (Suspension): Nach Rekonstitution mit Wasser enthält 1 ml Suspension zum Einnehmen 40 mg Voriconazol. Jede Flasche enthält 3000 mg
Voriconazol. Sonstige Bestandteile: Filmtabletten: Lactose-Monohydrat (50 mg: 63,42 mg; 200 mg: 253,675 mg), vorverkleisterte Stärke aus Mais, Croscarmellose-Natrium, Povidon, Magnesiumstearat (Ph.Eur.), Hypromellose,
Titandioxid (E171), Triacetin. Pulver (Infusionslösung): Natrium-beta-cyclodextrin-sulfobutylether (SBECD). 1 Durchstechflasche enthält 217,6 mg Natrium. Pulver (Suspension): Sucrose (540 mg/ml Suspension), hochdisperses
Siliciumdioxid, Titandioxid (E171), Xanthangummi, Natriumcitrat, Natriumbenzoat (E 211), wasserfreie Citronensäure, natürlicher Orangengeschmack. Anwendungsgebiete: invasive Aspergillose, Candidämie bei nicht neutropenischen Patienten, Fluconazol-resistente, schwere invasive Candida-Infektionen (einschl. C. krusei), schwere Pilzinfektionen durch Scedosporium spp. u. Fusarium spp. bei Erwachsenen u. Kindern ab 2 Jahren. In erster Linie
für Patienten mit progressiven, möglicherw. lebensbedrohlichen Infektionen. Gegenanzeigen: Überempfindlichk. gg. Voriconazol o. sonst. Bestandteile; Komedikation mit Terfenadin, Astemizol, Cisaprid, Pimozid, Chinidin,
Rifampicin, Carbamazepin, Phenobarbital, Mephobarbital, hochdos. Ritonavir od. Efavirenz (ab 400 mg tägl.), Ergotalkaloiden (Ergotamin, Dihydroergotamin), Sirolimus, Johanniskraut. Nebenwirkungen: Sehr häufig: Kopfsch.;
Sehstörungen (einschl. verschwommenen Sehen, Chromatopsie u. Photophobie); periph. Ödeme; Bauchschm., Übelk., Erbrechen, Durchfall; Hautausschlag; Fieber. Häufig: Gastroenteritis, Grippesympt.; Panzytopenie,
Knochenmarkdepression, Leukopenie, Thrombozytopenie, Anämie, Purpura; Sinusitis; Hypoglykämie, Hypokaliämie; Depressionen, Ängstlichk., Halluzinationen; Benommenh., Verwirrth., Tremor, Unruhe, Parästhesie; Thrombophlebitis, Hypotonie, Phlebitis; akutes Atemnotsyndr., Lungenödem, Atemnot, Brustschm.; Gelbsucht, cholestat. Gelbsucht; exfoliat. Dermatitis, Gesichtsödem, phototox. Reaktionen, makulopapulöser Hautausschlag, makulärer Hautausschlag, papulärer Hautausschlag, Cheilitis, Pruritus, Alopezie, Hautrötung; Rückenschm.; akute Niereninsuff., Hämaturie; erhöhte Leberwerte (einschl. ASAT, ALAT, alk. Phosphatase, GGT, LDH, Bilirubin), Erhöhung
d. Kreatininspiegels; Reaktionen/Entzündung an d. Inj.-stelle, Schüttelfrost, Asthenie. Gelegentlich: Verbrauchskoagulopathie, Agranulozytose, Lymphadenopathie, Eosinophilie; anaphylaktoide Reaktion, Überempfindlichk.
-reakt.; Nebennierenrindeninsuff.; Hirnödem, Ataxie, Doppeltsehen, Schwindel, Hypästhesie; Papillenödem, Störungen d. Sehnervs (einschl. optischer Neuritis), Nystagmus, Skleritis, Blepharitis; Kammerflimmern, ventrik.
Arrhythmien, Synkope, Vorhofarrhythmien, supraventrik. Tachykardie, Tachykardie, Bradykardie; Pankreatitis, Peritonitis, Duodenitis, Gingivitis, Glossitis, Zungenödem, Dyspepsie, Verstopfung; Leberinsuff., Hepatitis, Lebervergrößerung, Cholezystitis, Gallensteine; Stevens-Johnson-Syndrom, Quincke-Ödem, allerg. Dermatitis, Urtikaria, Arzneimittelexanthem, Psoriasis; Arthritis; Proteinurie, Nephritis; QT-Verlängerung im EKG, Erhöhung des
Harnstoffwerts im Blut, Hypercholesterinämie. Selten: pseudomembran. Kolitis; Hyperthyreose, Hypothyreose; Schlaflosigk.; Krampfanfall, Enzephalopathie, Guillain-Barré-Syndrom, extrapyramidal-motorisches Syndrom,
Schläfrigk. während d. Infusion, periph. Neuropathie; N.-opticus-Atrophie, Netzhautblutungen, okulogyre Krisen, Hornhauttrübungen; Hypakusis, Tinnitus; Torsade de pointes, ventrik. Tachykardie, kompl. AV-Block, Schenkelblock, AV-Rhythmus; Lymphangiitis; Geschmacksstör.; hepat. Koma; tox.-epiderm. Nekrolyse, Erythema multiforme, diskoider Lupus erythematodes, Pseudoporphyrie; Hypertonus; Nierentubulusnekrose. In Zusammenhang
mit schweren Grunderkr. selten schwere Lebertoxizität, Gelbsucht, Hepatitis u. Leberversagen mit Todesfolge. Häufigkeit nicht bekannt: Plattenepithelkarzinom. Periostitis. Die Erfahrungen nach der Markteinführung lassen
vermuten, dass Hautreaktionen (v. a. Erytheme) bei Kindern häufiger auftreten können als bei Erwachsenen. Warnhinweise und Vorsichtsmaßnahmen: Vorsicht bei Überempfindlichk. gg. Azole, bei Stör. d. Herzfkt. u. d.
Elektrolythaushalts, bei Komedikation nephrotox. Arzneimittel, bei Sympt. beginnender Leberschädigung, bei bestehendem Risiko akuter Pankreatitis, bei exfoliat. Hautreakt.; Pat., die mit VFEND behandelt werden, müssen
sorgfältig auf Lebertoxizität überwacht werden und VFEND muss ggf. abgesetzt werden. Es kam zu Phototoxizität u. Pseudoporphyrie. Alle Pat. einschl. Kinder sollten eine starke oder längere Sonnenlichtexposition vermeiden
und Schutzmaßnahmen wie entspr. Bekleidung u. Sonnenschutzmittel mit hohem LSF anwenden. Plattenepithelkarzinome a. d. Haut wurden bei Pat. beobachtet, v. denen einige über frühere phototox. Reaktionen berichtet
haben. Daher ist d. Notwendigk. e. Verringerung der VFEND-Exposition zu erwägen. B. Auftreten phototox. Reaktionen sollte Absetzen erwogen u. Pat. an Dermatologen überstellt werden. Bei Fortsetzen d. Therapie trotz
vorliegd. phototox. bedingt. Läsionen sollte e. system. u. regelm. dermatolog. Bewertung durchgeführt werden. Falls prämaligne Hautläsionen od. Plattenepithelkarzinome festgestellt werden, sollte VFEND abgesetzt werden.
Vorsicht vor infusionsbed. Reakt. Ggf. Dosisanpassung bei Komedikation mit Phenytoin, Rifabutin, Methadon, kurz wirks. Opiaten, Ritonavir, Efavirenz. Die gleichz. Gabe mit niedrig dosiertem Ritonavir muss vermieden werden
(Nutzen-Risiko-Abwägung!). Die gleichz. Gabe v. Everolimus wird nicht empfohlen, da erwartet wird, dass Voriconazol d. Konzentration v. Everolimus signif. erhöht. Die Filmtabletten enthalten Lactose u. sollten Patienten mit
d. seltenen, erblichen Krankheitsbild d. Galactose-Intoleranz, Lactase-Mangel o. gestörter Glucose-/Galactoseresorption nicht verabreicht werden. Der Natriumgehalt pro Durchstechfl. VFEND ist bei natriumkontrollierter Diät
zu berücksichtigen. Die Suspension zum Einnehmen enthält Sucrose u. darf bei Patienten mit seltenem, erblichen Krankheitsbild einer Fructose-Intoleranz, einem Sucrase-Isomaltase-Mangel o. einer gestörten Glucose-/Galactoseresorption nicht verabreicht werden. In der Schwangerschaft nur bei zwingender Indikation anwenden, ggf. wirksame Verhütungsmaßnahmen; bei zwingender Indikation in d. Stillzeit:
abstillen. Wegen unzureichender Daten zur Unbedenklichkeit u. Wirksamkeit kann VFEND für Kinder unter 2 Jahren nicht empfohlen werden. Bei d. intravenösen Darr.form darf d. Behandlungsdauer
6 Monate nicht überschreiten. B. Transplantat.-Pat. wurde üb. d. Auftr. e. nicht infektiösen Periostitis m. erhöh. Fluorid- u. Alkal.-Phosphotase-Spiegeln berichtet. B. Auftr. v. Schmerzen i. Bewegungsapparat
u. radiol. Befunden, d. e. Periostitis vermuten lassen: Abs. v. VFEND n. multidisziplin. Konsult. erwägen. Bitte beachten Sie außerdem die Fachinformation. Abgabestatus: Verschreibungspflichtig.
Pharmazeutischer Unternehmer: Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, Vereinigtes Königreich. Repräsentant in Deutschland: PFIZER PHARMA GmbH, 10785 Berlin. Stand: Juni 2013.
2
b-3v22vfe-0-0
* VFEND® ist zur Behandlung von invasiven Aspergillosen, Candidämien bei nicht neutropenischen Patienten, Fluconazol-resistenten, schweren invasiven Candida-Infektionen (einschließlich durch C. krusei) sowie zur
Behandlung schwerer Pilzinfektionen durch Scedosporien und Fusarien zugelassen.
1. Maschmeyer G, Haas A, Cornely OA. Drugs 2007; 67 (11): 1567-601.
2. Böhme A et al. Ann Hematol 2009; 88: 97-110. DGHO: Treatment of invasive fungal infections in cancer patients – Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of‚
Hematology and Oncology (DGHO).
3. Maschmeyer G et al. Eur J Cancer 2009; 45: 2462-2472. DGHO: Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German
Society of Haematology and Oncology.
4. Herbrecht R et al. 2009. ECIL-3: Meeting Juan-de-Pins, France, Sept 25-26, 2009, (http://www.ebmt.org/5WorkingParties/IDWP/wparties-id.html#ECIL09)
5. Walsh TJ et al. Clin Infect Dis 2008; 46: 327-360. IDSA: Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America.
6. Herbrecht R et al.: N. Eng. J. Med. 2002; 347, (6). In der Therapie invasiver Aspergillosen im Vergleich zu Amphotericin B.
Welcome to Content
the ICHS14 in Berlin
Welcome to the ICHS14 in Berlin......................................................................................... 4
Program Overview....................................................................................................................... 6
Scientific Program
Sunday, 15 June 2014.................................................................................................... 7
Monday, 16 June 2014................................................................................................... 7
Tuesday, 17 June 2014.................................................................................................10
Poster Presentation...................................................................................................................13
Speakers and Chairs.................................................................................................................18
General Information.................................................................................................................20
Information for Speakers and Poster Authors...............................................................21
Registration Fees.......................................................................................................................22
Commercial Part of the Conference
Satellite Symposia.....................................................................................................................24
List of Sponsors..........................................................................................................................26
FSA-List..........................................................................................................................................26
Something about Berlin..........................................................................................................27
Getting to Berlin........................................................................................................................28
Floor Plan......................................................................................................................................30
3
Welcome to the ICHS14 in Berlin
Dear colleagues and friends,
it is our greatest pleasure to welcome you in Berlin to the 18th biannual congress of the International
Immunocompromised Host Society (ICHS).
ICHS is the premier, international, multi-disciplinary forum for scientific and clinical interchange to
improve understanding and management of the immunocompromised host. It was founded in 1980
by an international group of experts engaged in all different aspects of immune deficiencies including
inborn errors, treatment-induced or transplant-associated immunosuppression as well as HIV infection
and others.
Our 18th international symposium will be held at the historical Langenbeck Virchow House, located
on the campus of the Charité University Hospital, founded in 1710, which has been the place where
Robert Koch, Rudolf Virchow, Paul Ehrlich and many other giants on the field of infectious diseases
have worked. We hope you all will have the opportunity to take home a few impressions from this
historical venue.
In this 18th ICHS congress we will address a number of highly attractive and scientifically hot topics
including
•
•
•
•
•
•
•
•
•
The microbiome
Infections in transplant recipients
Invasive fungal infections and resistance
Treatment of multi-resistant bacteria
Infectious complications in immunocompromised children
Life-threatening infections and intensive care in neutropenic cancer patients
Antiviral and antifungal immune responses in compromised hosts
The inflammasome
Prophylaxis and treatment of viral infections in immunocompromised hosts
A large number of outstanding experts will give their lectures and offer educational sessions during
our 3 days conference. We are looking forward to fruitful scientific exchange and personal communication with you all!
Best regards,
ICHS Executive Committee and Council
• Georg Maschmeyer, President, Germany
• Tom Patterson, President-elect, USA
• Claudio Viscoli, Past President, Italy
• Per Ljungman, Past President, Sweden
• Michael Boeckh, USA
• Eric Bow, Canada
•
•
•
•
•
4
Robert Finberg, USA
Jay Fishman, USA
Dimitrios Kontoyiannis, USA
Clarisse Machado, Brazil
Monica Slavin, Australia
Program Overview
5
Program Overview
Sunday, 15 June 2014
Time
13:00 – 15:00
15:30 – 16:15
Lecture Hall
2nd Floor
Satellite Symposium
Bernhard von
Langenbeck Room
1st Floor
Rudolf Virchow Room
2nd Floor
see commercial part
Opening Session –
Plenary Session #1
Satellite Symposium
16:30 – 18:30
see commercial part
18:30
Welcome Reception
08:00 – 09:00
Meet the expert #1
Infections in transplant
patients
Plenary Session #2
Monday, 16 June 2014
09:15 – 10:00
10:00 – 10:30
10:30 – 12:30
Meet the expert #3
Management of multiresistant bacteria
Coffee Break
Symposium #1
Neutropenic Fever
Syndromes
Symposium #2
Measuring Immune
Responses and
Infectious Risk in ICH
Satellite Symposium
12:30 – 14:00
14:00 – 14:30
14:45 – 16:15
16:15 – 16:45
17:00 – 19:00
Meet the expert #2
Infections in immunocompromised children
see commercial part
Plenary Session #3
Roundtable #1
Roundtable #2
Meet the expert #5
Vaccinations immunocompromised hosts
Meet the expert #6
Complicated infections
in cancer patients
Plenary Session #4
ICHS Member Meeting
Tuesday, 17 June 2014
08:00 – 09:00
09:15 – 10:00
10:00 – 10:30
10:30 – 11:30
11:30 – 12:30
12:30 – 14:00
14:00 – 14:45
15:00 – 17:00
17:00 – 18:00
Meet the expert #4
Risk stratification models
for opportunistic mycoses
Plenary Session #5
Coffee Break
Slide session:
Best abstract
presentation
Plenary Session #6
Lunch and Poster Discussion (organized)
Plenary Session #7
Symposium #3
Symposium #4
Joint Symposium
Unusual infections
ICHS & ESCMID/SCGICH
in unusual hosts
Farewell
6
Scientific Program | Sunday, 15 June 2014
Sunday, 15 June 2014
12:30 – 19:00
Registration Open
15:30 – 16:15
Opening Session – Plenary Session #1
Chairs: G. Maschmeyer (Potsdam, Germany)
T. Patterson (San Antonio, USA)
Microbiome
E. Pamer (New York, USA)
18:30
Welcome Reception
Lecture Hall
Scientific Program | Monday, 16 June 2014
Monday, 16 June 2014
07:30 – 17:30
Registration Open
08:00 – 09:00
Poster Mounting
09:00 – 18:00
Poster Exhibition Open
08:00 – 09:00
Meet-the-Expert Sessions
Meet-the-Expert #1:
Infections in Transplant Patients
J. Fishman (Boston, USA) & V. Morrison (Minneapolis, USA)
Meet-the-Expert #2:
B. v. Langenbeck Room
Infections in Immunocompromised Children
M. Santolaya (Santiago, Chile) & T. Lehrnbecher (Frankfurt, Germany)
Meet-the-Expert #3:
Management of Multiresistant Bacteria
R. Lewis (Bologna, Italy) & M. Akova (Ankara, Turkey)
09:15 – 10:00
Plenary Session #2
Meeting the Challenges of Multidrug Resistance in Febrile
Neutropenic Patients: Lessons Learned from the Pioneers
T. Walsh (New York, USA)
10:00 – 10:30
Coffee Break
7
Lecture Hall
R. Virchow Room
Lecture Hall
Scientific Program | Monday, 16 June 2014
10:30 – 12:30
Symposium #1: Neutropenic Fever Syndromes
Chairs: E. Bow (Manitoba, Canada)
C. Cordonnier (Creteil, France)
Lecture Hall
Risks Related to Neutropenic Fevers and Developing Complications
E. Bow (Manitoba, Canada)
Febrile Mucositis and its Importance to the Practice of Oncology
N. Blijlevens (Nijmegen, Netherlands)
Empirical Antibacterial Therapy in a Multi-Drug Resistant World
M. Akova (Ankara, Turkey)
Management of Severe Sepsis and Septic Shock Syndromes
T. Calandra (Lausanne, Switzerland)
10:30 – 12:30
Symposium #2: R. Virchow Room
Measuring Immune Responses and Infectious Risk in ICH
Chairs: J. Fishman (Boston, USA)
P. Grossi (Varese, Italy)
Host Response to CMV: Predictive Value
P. Reinke (Berlin, Germany)
Host Response to BK Virus
H. Hirsch (Basel, Switzerland)
Immunity in Fungal Infection: Important Markers
E. Roilides (Thessaloniki, Greece)
Vaccination of the Immunocompromised Host
M. Maeurer (Stockholm, Sweden)
14:00 – 14:30
Plenary Session #3
Chairs: C. Kauffman (Michigan, USA)
Pharmacokinetics of Antifungal Agents at Difficult Body Sites
R. Lewis (Bologna, Italy)
8
Lecture Hall
Scientific Program | Monday, 16 June 2014
14:45 – 16:15
Roundtable #1: B. v. Langenbeck Room
Infections in Cancer Patients: Hot Topics in 2014
Joint Session ICHS & German AGIHO
Chairs: C. Rieger (Munich, Germany)
H. Ostermann (Munich, Germany)
Bacteremia Due to Multidrug-Resistant Gram-Negative Bacteria in
Cancer Patients
J. Carratala (Barcelona, Spain)
Infection Control for Multidrug-Resistant Pathogens in Cancer Patients
P. Gastmeier (Berlin, Germany)
Anti-infective Stewardship in Hematology/Oncology
M. Slavin (Melbourne, Australia)
Role of Antibacterial Prophylaxis in Hematology in the Era of
Multidrug-Resistance
C. Viscoli (Genova, Italy)
Supported by an Unrestricted Educational Grant by Gilead Sciences
14:45 – 16:15
Roundtable #2: Viral Infections in Transplant Recipients
Chairs: P. Ljungman (Stockholm, Sweden)
H. Hirsch (Basel, Switzerland)
Recent Developments in Antiviral Therapy
M. Boeckh (Seattle, USA)
Old and New Respiratory Viruses
L. Kaiser (Geneva, Switzerland)
Viral Hepatitis
T. Berg (Leipzig, Germany)
16:15 – 16:45
Plenary Session #4
Chairs: M. Boeckh (Seattle, USA)
J. Fishman (Boston, USA)
New Developments in CMV Vaccination
P. Griffiths (London, UK)
17:00 – 19:00
ICHS Member Meeting
19:30
Social Event at Restaurant “Habel Weinkultur”
9
R. Virchow Room
Lecture Hall
Lecture Hall
Scientific Program | Tuesday, 17 June 2014
Tuesday, 17 June 2014
07:30 – 17:00
Registration Open
08:00 – 16:00
Poster Exhibition Open
08:00 – 09:00
Meet-the-Expert Sessions
Meet-the-Expert #4: Risk Stratification Models for Opportunistic Mycoses
C. Cordonnier (Creteil, France) & R. Lewis (Bologna, Italy)
Meet-the-Expert #5: B. v. Langenbeck Room
Vaccinations in Immunocompromised Hosts
P. Ljungman (Stockholm, Sweden) & C. Machado (São Paulo, Brazil)
Meet-the-Expert #6: R. Virchow Room
Complicated Infections in Cancer Patients
M. Slavin (Melbourne, Australia) & T. Patterson (San Antonio, USA)
09:15 – 10:00
Plenary Session #5
Chairs: M. Slavin (Melbourne, Australia)
R. Finberg (Worcester, USA)
ICU Critically Ill Neutropenic Cancer Patients
E. Bow (Manitoba, Canada)
Who Should be Offered ICU?
E. Azoulay (Paris, France)
10:00 – 10:30
Break
10
Lecture Hall
Lecture Hall
Scientific Program | Tuesday, 17 June 2014
10:30 – 11:30
Slide Session:
Best Abstract Presentations Chairs: G. Maschmeyer (Potsdam, Germany)
C. Viscoli (Genova, Italy)
B. v. Langenbeck Room
P9
Deep Sequencing Reveals Restrictions and Patterns of Evolution of Influenza
R. Finberg (Boston, USA)
P26 Diagnostic Performance of Lateral Flow Device and Galactomannan for
the detection of Aspergillus in Bronchoalveolar Fluid of Patients At High
Risk For Invasive Aspergillosis.
M.H. Miceli, (Ann Arbor, USA )
P36
Vaccine Prevention in Solid Organ Transplantation (SOT) Candidates and
Recipients: A systematic Approach is Needed
N. Enriquez (Geneva, Switzerland)
P56
Modulatory Role of Nuclear Receptors on the C. albicans – Induced Immune
Response in Human Monocytes
H. Slevogt (Jena, Germany)
11:30 – 12:30
Plenary Session #6
Chairs: C. Machado (Sao Paulo, Brazil)
T. Walsh (New York, USA)
Inflammasome Activation and Regulation
E. Latz (Bonn, Switzerland)
Impact on Host Response
R. Finberg (Worcester, USA)
12:30 – 14:00
Lunch & Poster Discussion
Chair: P. Ljungman (Stockholm, Sweden)
14:00 – 14:45
Plenary Session #7
Chairs: T. Patterson (San Antonio, USA)
R. Lewis (Bologna, Italy)
Lecture Hall
Poster area Floor 1 and 2
Lecture Hall
Management of Breakthrough Fungal Infections in Patients on Systemic Antifungal Prophylaxis
D. Kontoyiannis (Houston, USA)
11
Scientific Program | Tuesday, 17 June 2014
15:00 – 17:00
Symposium #3: Joint Symposium ICHS & ESCMID/SCGICH
Chairs: M. Akova (Ankara, Turkey)
T. Patterson (San Antonio, USA)
Lecture Hall
Recent Developments in Epidemiology, Diagnosis, and Treatment of
Pneumocystis
J. Fishman (Boston, USA)
Non-Culture Based Diagnosis of Invasive Fungal Disease
J.P. Donnelly (Nijmegen, Netherlands)
Aspergillosis in ICU Patients: Epidemiology and Clinical Outcomes
M. Bassetti (Udine, Italy)
Galactomannan or PCR for Pre-Emptive Use of Antifungals in Hematology Patients?
J. Aguado (Madrid, Spain)
15:00 – 17:00
Symposium #4: Unusual Infections in Unusual Hosts
Chairs: D. Kontoyiannis (Houston, USA)
O.A. Cornely (Cologne, Germany)
Chronic Granulomatous Disease
B. Segal (Buffalo, USA)
Collagen Vascular Diseases
C. Kauffman (Michigan, USA)
Premature Neonates
E. Roilides (Thessaloniki, Greece)
Existing Lung Disease
P. Corris (Newcastle upon Tyne, UK)
17:00
Farewell
12
B. v. Langenbeck Room
Poster Presentations
P1
Disseminated Histoplasmosis in Children with Acute Lymphoblastic Leukemia & Hemophagocytic Lymphohistocytosis.
S. Green, K. Macotti, C. Pacheco, M. Richards, K. Belani ..................................................................USA
P2 Spectrum of Bacteremia in Bone Marrow Transplant Patients from A Tertiary Care Hospital in India
A. Ghafur, V. PR Devarajan, C.K. Kokila, V. Nagvekar........................................................ South India
P3 Pneumonia in Patients with Influenza
S. Pavic, M. Jovanovic.................................................................................................................................Serbia
P4 Cytomegalovirus Specific T Cell Responses in Kidney Transplant Recipients.
HK Doğan, E. Mutlu, S. Köksoy, A Dinçkan, V.T. Yilmaz, H. Koçak, I. Aliosmanoğlu, D. Çolak,
D. Mutlu, F. Günseren, G. Süleymanlar, M. Gultekin.................................................................... Turkey
P5 Development of a Software to Support Diagnosis of Brain Lesions of Suspected Infectious Origin Starting from an International Database and a Set of Radiologic Image Analysis Tools.
N. Maximova, F. Zennaro, D. Grosso, D. Zanon, A. Pizzol, T. Minuzzo, R. Torelli................... Italy
P6 Changing the Quantitative Cytomegalovirus (CMV) PCR Test in the Clinical Microbiology Laboratory which is used for Follow Up Transplant Recipients: Do the Results Differ?
D. Colak, I. Saglik, D. Mutlu, B. Ozhak Baysan, G. Ongut, D. Ogunc, M. Gultekin.............. Turkey
P7 Comparison of Cytomegalovirus Infection and Disease After Allogeneic Stem Cell Transplant
from Haploidentical and Unrelated Donors in Adults with Acute Myelogenous Leukemia.
H.-J. Lee, S. Choi, S. Cho, D. Lee..............................................................................................................Korea
P8 Compartmentalization of cytomegalovirus in central nervous system of haematopoietic stem cell transplant patients during the course of treatment
B. Cherng, T.T. Tan, B.H. Tan, A. YL Ho, YC Linn.........................................................................Singapore
P9 Deep Sequencing Reveals Restrictions and Patterns of Evolution of Influenza
K.B .Zeldovich, D.N.Bolon, D.R. Caffrey, N. Renzette, P. Liu, T.F. Kowalik, C.A. Schiffer, R.W. Finberg,
J.P. Wang...............................................................................................................................................................USA
P10 Antibody response to influenza vaccination in kidney and lung transplant recipients in comparison to healthy controls: Preliminary data of a collaborative study Brazil-Sweden
L.S. Vilas Boas, M.C. Salles, S.V. Campos, M. Maeurer, A. Ambati, P. Ljungman,
C.M. Machado.......................................................................................................................... Brazil & Sweden
P11 Invasive Fungal Infections in Patients with Myeloma in the Era of Novel Myeloma Agents
B.W. Teh, J.C. Teng, K. Urbancic, A. Grigg, S.J. Harrison, L.J .Worth, M.A. Slavin,
K.A. Thursky................................................................................................................................................ Australia
P12 The Role of HLA-Driven Viral Adaptation in Immune Control of HIV Infection in a Maternal Population in Durban, South Africa
A. Hempenstall, M. Muenchhoff, E. Adland, S. Singh, A. Carlqvist, T. Ndung’u,
P. Goulder................................................................................................................................................................ UK
13
Poster Presentations
P13 A PCR-based tool for Aspergillus fumigatus detection in the context of Invasive Aspergillosis
J. Bourdin, A. Iannello, C. Blanc, M. Lackner, J. Springer, L. Estève, C. Lass-Flörl, J. Löffler,
H. Einsele, A. Pachot, J. Yugueros-Marcos, A. Apostolaki.............. France, Austria, & Germany
P14 Aspergillus fumigatus RNA detection tool in the context of Invasive Aspergillosis
M. Lacroix, D. Filiputti, M. Mercey, C. Caneiro, J. Springer, M. Lackner, L. Estève, C. Lass-Flörl, J. Löffler,
H. Einsele, A. Pachot, J. Yugueros-Marcos, A. Apostolaki.............. France, Austria, & Germany
P15 Value of voriconazole drug monitoring in immunocompromissed children and adolescent
F. Carlesse, A.A. Senerchia, A.C. Marco, A.L. Colombo.................................................................... Brazil
P16 Diagnosis of pathogens and antimicrobial resistance genes of bloodstream infections in
pediatric oncologic patients by real time PCR.
F. Carlesse, M.G. Quiles, A.C. Marcos, A.C. Pignatari........................................................................ Brazil
P17 Epstein-Barr virus in the cerebrospinal fluid: pathogen or innocent bystander? Observational
cross-sectional study
R. Moroti, I.D. Olaru, R.M. Hrisca, A. Hristea, A. Petrescu, V. Arama, O. E. Benea, D. Otelea,
A. Streinu-Cercel, D. Florea.................................................................................................................. Romania
P18 Changes in the Epidemiology of Candida Associated Bloodstream Infections and Antifungal
Resistance in Adult Patients from 2001 to 2009.
A. Cuartas-Abril, P. Vermehern, J. Cawley, J. Mendez........................................................................USA
P19 Influenza A H1N1: five years of diagnostics in Brazil
C.S. Lázari, D.S. Pereira, E.R.M. Silva, J. de Sá, J.L.M. Sampaio, C.F.H. Granato..................... Brazil
P20 Epidemiology, clinical characteristics, risk factors and outcomes of Carbapenem Resistant
Enterobacteriaceae (CRE) colonization and infections among an Asian Liver transplant (LTx) cohort
J. Soh, Y.X. Liew, A.L. Kwa, C.K. Tan, B.H. Tan, T.T. Tan.............................................................Singapore
P21 Proven Invasive Aspergillosis in an All Pediatric Patient Under Chemotherapy in ICU
C. Lameiras, F. Coelho, V. Costa, M. Rochas, M.A Guimaraes, F. Faria................................ Portugal
P22 Cellulitis of Carbapenem Resistant Pseudomonas Aeruginosa in Neutropenic Patient.
G. Ozgur, G. Mert, I. Erturk, F. Avcu, O. Nevruz, K. Kaptan, T. Çetin................................................ Turkey
P23 A Case Report of Cutaneous Aspergillosis
G. Mert, C. Artuk, G. Ozgur, F. Avcu, O. Nevruz, T. Çetin............................................................... Turkey
P24 Risk Factors and Outcomes associated with Ganciclovir Resistant Cytomegalovirus Infection
Following Solid Organ Transplantation: A Retrospective Study
C.E. Fisher, J.L. Knudsen, M. Boeckh, A.P. Limaye................................................................................USA
P25 Randomized Double-Blind Trial of Andidulafungin vs Fluconazole for Prophylaxis of Invasive
Fungal Infections in High-Risk Liver Transplant Recipients.
D.J. Winston, A.P. Limave, S. Pelletier, N. Safdar, M.I. Morris, K. Meneses, R.W. Busuttil,
N. Singh.................................................................................................................................................................USA
14
Poster Presentations
P26 Diagnostic Performance of Lateral Flow Device and Galactomannan for the detection of
Aspergillus in Bronchoalveolar Fluid of Patients At High Risk For Invasive Aspergillosis.
M.H. Miceli, M.I. Goggins, P. Chander, A.K. Sekaran, A.E. Kizy, L. Samuel, H. Jiang, C.R. Thornton,
M. Ramesh, G. Alangaden.................................................................................................................. USA & UK
P27 Molecular Epidemiology of Bacteremia Caused by B. Cerceus in Pediatric Cancer Ward.
J.M. Min Kim, S. Ja Kim ,Y. Kim, K. Park, S. Jin Kim, K. Hee Yoo, K. Woong Sung, H. Hoe Koo,
N. Yong Lee, Y. Kim.........................................................................................................................................Korea
P28 Pneumocystis jirovicii pneumonia in pediatric patients: An analysis of 16 confirmed conse
cutive cases during 14 years
K.R. Kim, J. Min Kim, S. Lee, K. Yoo, K. Sung, H. Koo, Y. Kim........................................................Korea
P29 A case of severe anemia caused by parvovirus infection in a kidney transplantation recipient
K.R. Kim, Y. Kim, S. Lee................................................................................................................................Korea
P30 Epidemiology of Multi-Resistant Organism Bacteraemias in Haematological Malignancy and
HSCT Patients – Single Center Experience, Sydney, Australia
W. Wu, S. Chen, P.E. Ferguson.......................................................................................................... Australia
P31 Functional Endoscopic Sinus Surgery in Immunocompromised Children: 9 Years’ Experience
from the Schneider Children’s Medical Center of Israel.
S. Fischer, J. Stein, I. Yaniv, E. Yaniv...................................................................................................... Israel
P32 Molecular Characterization of DC Sign Promoter in HIV Infected Pregnant Women
S. Singh, S. Khare, S. Prasad, P. Gupta, H. Ram, A. Rai.................................................................... India
P33 Posaconazole versus Fluconazole or Itraconazole Prophylaxis in Patients with Acute Myeloid
Leukemia or Myelodysplastic Syndrome undergoing Cytotoxic Chemotherapy: Perspectives
in Korea
D.-G. Lee, S. Cho, J. Choi, H. Lee, S. Choi.............................................................................................Korea
P34 Performance of QuantiFERON TB Gold Test Compared With the Tuberculin Skin Test for
Detecting Latent Tuberculosis Infection in Lung and Heart Transplant Candidates
M. Mardani, M. Farshidpour, M. Nekoonam, F. Varahram, K. Najafizadeh, N. Mohammadi,
B. Sharifkashani, L. Gachkar, B. Farokhzad, A. Droudinia, P. Javanmard, P. Tabarsi............... Iran
P35 Performance of QuantiFERON TB Gold Test in detecting latent tuberculosis infection in
brain-dead organ donors, in Iran: A Brief Report
P. Tabarsi, A. Yousefzadeh, K. Najafizadeh, A. Droudinia, R. Bayati, M. Marjani, S. Shafaghi,
B. Farokhzad, P. Javanmard, A. Akbar Velayati ..................................................................................... Iran
P36 Vaccine Prevention in Solid Organ Transplantation (SOT) Candidates and Recipients:
A Systematic Approach is Needed
N.B. Enriquez, C. van Delden, C.A. Siegrist............................................................................ Switzerland
15
Poster Presentations
P37 Depletion of Dendritic cells and lack of expression of MIP3alpha in oral hairy leukoplakia in
HIV positive patients
M. Palmieri, M. Gallottini, P.H. Braz-Silva.......................................................................................... Brazil
P38 Diversity of C subgenotype of HHV- 8 found in the saliva of HIV-infected individuals without
KS under the use of HAART in Brazil
P.H. Braz-Silva, T.R. Tozetto Mendoza, L.M. Sumita, W.S. Freire, V. Ueda Fick De Souza,
C.S. Pannuti....................................................................................................................................................... Brazil
P39 Varicella zoster virus (VZV) disease of the central nervous system (CNS) following kidney
transplantation
E. Renoult, S. Lanthier, D. Rouleau, N. Dodoin, M. Pâquet, G. St-Louis, A. Duclos, L. St-Jean,
M. Léveillé, M.C. Fortin, C. Girardin, and M.J. Hébert................................................................... Canada
P40 Clinical impact of infection with nontuberculous mycobacteria in patients with underlying
malignant disease
B. Hermann, T. Rachow, B. Schleenvoigt, J. Rödel, K. Meckel, A. Hochhaus,
M. von Lilienfeld-Toal........................................................................................................................Germany
P41
Case report: Elevated Serum Galactomannan Levels After Autologous Stem Cell Transplantation
T. Rachow, S. Dornaus, H.G. Sayer, B. Hermann, A. Hochhaus,
M. von Lilienfeld-Toal........................................................................................................................Germany
P42
Active surveillance of infections caused by multidrug-resistant gram-negative bacteria in a
Solid Organ Transplantation Department
A. Geladari, T. Karampatakis, O. Tsiatsiou, V. Pentsioglou, P. Christoforou, E. Iosifidis,
C. Antachopoulos, V. Papanikolaou, E Roilides................................................................................ Greece
P43
Effects of Human Polymorphonuclear Neutrophils (HPNs) Alone or in Combination with
Four Antipseudomonal Antibiotics against Pseudomonas aeruginosa Biofilms
A. Chatzimoschou, M. Simitsopoulou, T.J. Walsch, E. Rolides................................................. Greece
P44
Identification of New Molecular Targets for Antifungal Agents in Candida albicans Biofilms
A. Chatzimoschou, M. Simitsopoulou, T.J. Walsch, E. Rolides................................................. Greece
P45
Results of multi-center retrospective study on proven and probable invasive mycosis in
hemato-oncological pediatric patients.
V. Baretta, G. Tridello, E. Calore, E. Castagnola, F. Carraro, I. M., A. Colombini, K. Perruccio,
N. Decembrino, M. La Spina, N. Maximova, D. Caselli, S. Cesaro.................................................. Italy
P46
Tri-Reg –A Europe-wide Study of Trichosporonosis
K. Wahlers, M. JGT Vehreschild, C. Lass-Flörl, O.A. Cornely on behalf of the ECMM Working
Group Members.......................................................................................................................................Germany
P47
FungiscopeTM – Global Emerging Fungal Infection Registry
K. Wahlers, M. J.G.T. Vehreschild, H. Wisplinghoff, S. de Hoog, J..J. Vehreschild and O.A. Cornely
on behalf of The Fungiscope ECMM/ISHAM Working..............................................................Germany
16
Poster Presentations
P48
Neutropenic Infection control precautions in South India – a report
D.S. Kumar, J.Hemalatha........................................................................................................................... India
P49
Bacterial and Fungal Infections in the Early Period After Liver, Kidney, Simultaneous Pancrease
and Kidney Transplantation – Etiological Agents and Susceptibility to Antimicrobial Drugs
D. Kawecki, A. Chmura, G. Młynarczyk.............................................................................................. Poland
P50
Comparison of Two Methods for Rapid Identification of Blood Pathogens in Cancer Patients
with Sepsis
N. Dmitrieva, N. Bagirova, I. Petukhova, Z. Grigoryevskaya, S. Dyakova, I. Shilnikova........ Russia
P51
An outbreak of nosocomial infection caused by multidrugresistant (MDR) Klebsiella pneumoniae in the largest cancer hospital in Russia
N. Dmitrieva, Z. Grigoryevskaya, I. Petukhova, N. Bagirova, I. Shilnikova, S. Dyakova........ Russia
P52 Taxonomic structure of sepsis pathogens in ICU patients in Cancer Research Center of Russia
for 3-year period.
I. Petukhova, N. Dmitrieva, N. Bagirova, S. Dyakova, Z. Grigoryevskaya, I. Shilnikova........ Russia
P53 Dynamics of Clostridium Difficile-associated Diarrhea in the Russian Cancer Research Center
I. Petukhova, N. Dmitrieva, I. Shilnikova, N.Bagirova, S.Dyakova, Z. Grigoryevskaya.......... Russia
P54 Bloodstream Infection in Patients with Hematological Malignancies and Febrile Neutropenia
Mortality-Related Factors
G.A. Méndez, C. Niveyro, O.A. Sosa, H.I. Bernard, M.M. Beligoy, A.V. D´Elia,
C.A. Devecchi........................................................................................................................................... Argentina
P55 Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry identification
of nontuberculous mycobacterial species in lung transplant recipient
I. Mareković, G. Pavliša, Z. Bošnjak, V. Plečko.............................................................................. Croatia
P56 Cost Effective Management of Chronic Hepatitis C Patients in a Clinic Setting
C.T. Chizea, M.O. Asperilla, D.M. Klein, J.H. Villadarez........................................................................USA
P57 Modulatory role of nuclear receptors on the C. albicans-induced immune response in human
monocytes
T.E. Klassert, A. Hanisch, J. Bräuer, M.K. Mansour, J.M. Vyas, J.M. Tam, H. Slevogt..........Germany
P58 Improving the Outcomes of Cancer Patients with Multidrug-Resistant Gram Negative Rods
Bloodstream Infections
N. Mori, A.El Zakhem, P. Williams, S. Cantu, J. Tarrand, I. Raad, R. Chemaly, J. Adachi.......USA
P59 Emergency Liver Transplantation Despite Actively Ongoing Systemic Bacterial Infection
D.L. Vu, C. Toso, T. Berney, P. Majno, E. Giostra, I. Morard, G. Mentha,
C. van Delden...................................................................................................................................... Switzerland
P60 Gastric Mucormycosis In A Child With Acute Myelogenous Leukemia
S.S. Eissa...........................................................................................................................................................Egypt
17
Speakers and Chairs
Adachi, J., Houston, USA
Aguado, J.M., Madrid, Spain
Akova, M., Ankara, Turkey
Apostolaki, A., Grenoble, France
Azoulay, E., Paris, France
Baretta, V., Verona, Italy
Bassetti, M., Udine, Italy
Belani, K., Minneapolis, USA
Berg, T., Leipzig, Germany
Blijlevens, N.M.A., Nijmegen, Netherlands
Boeckh, M., Seattle, USA
Bow, E., Manitoba, Canada
Braz-Silva, P.H., São Paulo, Brazil
Calandra, T., Lausanne, Switzerland
Carlesse, F., São Paulo, Brazil
Carratala, J., Barcelona, Spain
Chatzimoschou, A., Thessaloniki, Greece
Cherng, B., Singapore
Chizea, C.T., USA Colak, D., Antalya, Turkey
Cornely, O.A., Colgne, Germany
Cordonnier, C., Creteil, France
Corris, P., Newcastle upon Tyne, UK
Devarajan, V., Chennai, South India
Dmitrieva, N., Moscow, Russia
Donnelly, J.P., Nijmegen, Netherlands
Eissa, S.S., Cairo, Egypt
Enriquez, N. B., Geneva, Switzerland
Ferguson, P.E., Sydney, Australia
Finberg, R.W., Worcester, USA
Fischer, S., Petah Tikva, Israel
Fisher, C.E., Seattle, USA
Fishman, J., Boston, USA
Gastmeier, P., Berlin, Germany
Geladari, A., Thessaloniki, Greece
Griffiths, P., London, UK
Grossi, P., Varese, Itlay
Gultekin, M., Antalya, Turkey Hempenstall, A., Oxford, UK
Hermann, B., Jena, Germany
Hirsch, H., Basel, Switzerland
Kaiser, L., Geneva, Switzerland
Kauffman, C., Michigan, USA
Kawecki, D., Warsaw, Poland
Kim, J. M., Seoul, Republic of Korea
Kim, K. R., Seoul, Republic of Korea
poster no. 58
p. 12
p. 7, 8, 12
poster no. 13, 14
p. 10
poster no. 45
p. 12
poster no. 1
p. 9
p. 8
p. 9
p. 8, 10
poster no. 37, 38
p. 8
poster no. 15, 16
p. 9
poster no. 43, 44
poster no. 8
poster no. 56
poster no. 6
p. 12
p. 8, 10
p. 12
poster no. 2
poster no. 50, 51
p. 12
poster no. 60
poster no. 36, p. 11
poster no. 30
poster no. 9, p.11
poster no. 31
poster no. 24
p. 7, 8, 9, 12
p. 9
poster no. 42
p. 9
p. 8
poster no. 4
poster no. 12
poster no. 40
p. 8, 9
p. 9
p. 8, 12
poster no. 49
poster no. 27
poster no. 28, 29
18
Speakers and Chairs
Kontoyiannis, D., Houston, USA
Kumar, D.S., India
Lameiras, C., Porto, Portugal
Latz, E., Bonn, Germany
Lázari, C.S., São Paulo, Brazil
Lee, H.-J., Seoul, Republic of Korea
Lee, D.-G., Seoul, Rupublic of Korea
Lehrnbecher, T., Frankfurt, Germany
Lewis, R., Bologna, Italy
Ljungman, P., Stockholm, Sweden
Machado, C.M., São Paulo, Brazil
Maeurer, M., Stockholm, Sweden
Mareković, I., Zagreb, Croatia
Maschmeyer, G., Potsam, Germany
Maximova, N., Trieste, Italy
Mendez, J., Jacksonville, USA
Méndez, G.A., Posadas, Argentina
Mert, G., Ankara, Turkey
Miceli, M.H., Ann Arbor, USA Moroti, R., Bucharest, Romania
Morrison, V., Minneapolis, USA
Ostermann, H., Munich, Germany
Pamer, E., New York, USA
Patterson, T., San Antonio, USA
Pavic, S., Uzice, Serbia
Petukhova, I., Moscow, Russia
Rachow, T., Jena, Germany
Reinke, P., Berlin, Germany
Renoult, E., Montréal, Canada
Rieger, C., Munich, Germany
Roilides, E., Thessaloniki, Greece
Santolaya, M.E., Santiago, Chile
Segal, B., Buffalo, USA
Singh, S., Dehli, India
Slavin, M., Melbourne, Australia
Slevogt, H., Jena, Germany
Soh, J., Singapore
Tabarsi, P., Tehran, Iran
Teh, B.W., Melbourne, Australia
Viscoli, C., Genova, Italy
von Lilienfeld-Toal, M., Jena, Germany
Vu, D.L., Geneva, Switzerland
Wahlers, K., Cologne, Germany
Walsh, T., New York, USA
Winston, D.J., Los Angeles, USA
p. 11, 12
poster no. 48
poster no. 21
p. 11 poster no. 19
poster no. 7
poster no. 33
p. 7
p. 7, 8, 10, 11
p. 9, 10, 11
poster no. 10, p. 10, 11
p. 8
poster no. 55
p. 7, 11
poster no. 5
poster no. 18
poster no. 54
poster no. 22, 23
p. 11, poster no. 26
poster no. 17
p. 7
p. 9
p. 7
p. 7, 10, 11, 12
poster no. 3
poster no. 52, 53
poster no. 40
p. 8
poster no. 39
p. 9
p. 8, 12
p. 7
p. 12
poster no. 32
p. 9, 10
poster no. 57, p. 11
poster no. 20
poster no. 34, 35
poster no. 11
p. 9, 11
poster no. 40, 41
poster no. 59
poster no. 46, 47
p. 7, 11
poster no. 25
19
General Information
Venue
Langenbeck-Virchow-Haus
Luisenstr. 58/59
10117 Berlin, Germany
Organizer
The International Immunocompromised Host Society (ICHS)
Congress and
ICHS President
Georg Maschmeyer
Professor of Internal Medicine
Chair, Dept. of Hematology, Oncology and Palliative Care
Director, Center for Hematology, Oncology and Radiotherapy
Klinikum Ernst von Bergmann
Charlottenstr. 72, 14467 Potsdam, Germany
ICHS Executive
Committee and Council
Georg Maschmeyer, President, Germany
Tom Patterson, Vice President, USA
Per Ljungman, Past President, Sweden
Claudio Viscoli, Past President, Italy
Michelle Trimble, Executive Secretary, USA
Website
Conference Language
www.ichs.org
Congress Organization
INTERPLAN Congress, Meeting & Event Management AG
Landsberger Str. 155
80687 Munich, Germany
Phone: +49 89 54 82 34 – 771
E-Mail: [email protected]
Opening hours
registration desk
Sunday, 15 June 2014
Monday, 16 June 2014
Thuesday, 17 June 2014
English
12:30 – 19:00
07:30 – 17:00
07:30 – 17:00
Certificate of Attendance Participating delegates will receive a CME Certificate of Attendance at the registration desk on-site before departure.
The ICHS-Conference has been approved for 16 CME points by Ärzte-
kammer Berlin
Hotel Reservation
There are a number of lodging options located near the meeting venue. For rates and email reservations, please contact [email protected].
20
Information for Speakers and Poster Authors
Information for Poster Authors
Please notice the following when preparing your poster:
• Poster dimensions should not exceed a common poster size of 90 cm x 120 cm (DIN A0)
• State the title and the authors at the top of your poster in easily readable bold letters
• Indicate the presenting author if different from the first author
• The text and the illustrations should be readable from a distance of 2 meters
The posters will be presented in a poster discussion on Tuesday, 17 June 2014, 12:30 – 14:00.
Two experts will discuss and comment the posters and involve the authors in the discussion. The
authors of the posters are requested to attend the poster discussion. The poster discussion posters
will be exhibited in a dedicated area in 1st and 2nd floor.
Information for Speakers
Opening Hours of the Media Check Room (1st floor)
Sunday, 15 June 2014 12:30 – 18:30
Monday, 16 June 2014 07:30 – 17:00
Tuesday, 17 June 2014 07:30 – 17:00
It is not possible to bring your presentation directly to the lecture hall. All presentations have to
be delivered at the Media Check Room. Our competent technical staff will be at your disposal. The
facilities in the Media Check Room will provide the possibility of:
• reviewing your PowerPoint presentation
• uploading your PowerPoint presentation for the dedicated session conference room
All presentations will be supervised by the centralized Media Check Room. Here, the material for
presentation must be delivered by the speakers at least 1 hour prior to the session.
21
Registration Fees
Registration Rates*
Standard Registration
ICHS Member
€ 475,-
Emeritus Members
€ 295,-
Non-Members
€ 675,-
ICHS Trainee Member
€ 275,-
* VAT not applicable due to §4 Nr. 22a UStG; received by order and for account of The International Immunocompromised Host Society.
Evening Events**
Date
Euro
Welcome Reception at the Langebeck-Virchow-House
June 15 , 2014
€ 0,-
ICHS Social Event at the Habel Restaurant**
June 16th, 2014
€ 65,-
th
** incl. 19 % German VAT; received by order of INTERPLAN AG, Landsbergerstr. 155, 80687 Munich.
VAT ID: DE 213274875 and for the account of The International Immunocompromised Host Society.
Delegate‘s Registration Fee includes:
•
•
•
•
Access to the Scientific Sessions & Industrial Exhibition
Coffee Breaks
Welcome Reception
Printed version of the Final Congress Program onsite
Booking terms and conditions:
Payment is possible by direct debit, bank transfer and credit card.
Cancellation:
All cancellations and amendments must be submitted in writing to the Conference Office via fax (+49 89 54 82 34 44)
or email to [email protected]. Cancellations received in writing prior to May 23th, 2014 will receive a 100 % refund,
but with a processing fee of € 20,-. No refund will be given after this date, however an alternative delegate name may
be submitted.
Data protection notice:
Our company handles all personal data according to the laws of §4 under the Federal Data Protection Act. For your
registration to the above mentioned congress the collecting, saving and processing of your personal data is imperative.
This is done solely as a means to the organization and completion of the event.
Your data will only be passed onto a third party, who is directly involved with the running of the Congress and when
the organizational procedure makes this necessary (operator, hotel).
The legislator requires us to obtain your consent. The registration to this congress is not possible if we do not get this.
I hereby declare my consent that all the information made by me to my person within the handling of the above
mentioned congress is filed, saved, processed and the demands made above can correspondingly be passed onto a
third party. I agree to receive information on future congresses related to the subject of this event. Declaration of
consent can be retracted at any time by sending a message to INTERPLAN AG, Landsberger Str. 155, 80687 Munich,
or [email protected].
22
Commercial Part
of the Conference
Satellite Symposia
Sponsors
FSA-List
Something about Berlin
Getting to Berlin
23
Satellite Symposia
Sunday, 15 June 2014
13:00 – 15:00
Satellite Symposium Lecture Hall
organized by Merck Sharp & Dohme Corp.
Anti Mold Prophylaxis: Advances in Prevention of Invasive Fungal Infections
Chair: O.A. Cornely (Cologne, Germany)
13:00–13:05
Welcome and Opening Remarks – O.A. Cornely (Cologne, Germany)
13:05–13:30
Pharmacologic Principles and Clinical Evidence for the Management of
Mucormycosis. – D. Kontoyiannis (Houston, USA)
13:30–13:55
Therapeutic Drug Monitoring: necessary for prophylaxis? –
D. Sheppard (Monteral, Canada)
13:55–14:20
Phase 1B study of the Pharmacokinetics and Safety of Posaconazole Solid
Oral Tablet in Patients at Risk for Invasive Fungal Infection (IFI) –
R. Duarte (Barcelona, Spain)
14:20-14:45
Phase 3 Study of the Pharmacokinetics and Safety of Posaconazole Solid
Oral Tablet in Patients at Risk for Invasive Fungal Infection (IFI) –
O.A. Cornely (Cologne, Germany)
14:45–14:55
Discussion
14:55–15:00
Closing Remarks – O.A. Cornely (Cologne, Germany)
16:30 – 18:30
Satellite Symposium B. v. Langenbeck Room
organized by Pfizer Pharma Management of infections in the immunocompromised patient
Chair: G. Maschmeyer (Potsdam, Germany)
16:30 – 16:40
Welcome – G. Maschmeyer (Potsdam, Germany)
16:40 – 17:05
Management of infections with multiresistant pathogens in the immunocom-
promised patient – M. Deja (Berlin, Germany)
17:05 – 17:30
Azol Antifungals in high-risk patients – C. Rieger (Munich, Germany)
17:30 – 17:55
Impact of latent virus infections on the clinical course of SOT-patients –
P. Reinke (Berlin, Germany)
17:55 – 18:20
Vaccinations in immunocompromised patients – U. Baumann (Hanover, Germany)
18:20 – 18:30
Discussion, Closing remarks – G. Maschmeyer (Potsdam, Germany)
24
Satellite Symposia
Monday, 16 June 2014
12:30 – 14:00 Satellite Symposium B. v. Langenbeck Room
organized by Astellas Pharma
Clinical Problem Solving in Transplant Patients and Immunocompromised Hosts
12:30 – 12:35
Introduction – J.M.. Aguado (Madrid, Spain)
12:35 – 13:00
Liver transplantation in the MELD era – infection risks, prophylaxis, trends –
L. Fischer (Hamburg, Germany)
13:00 – 13:25
Clostridium difficile infection (CDI) in immunocompromised patients –
minimising risks, managing consequences – O.A. Cornely (Cologne, Germany)
13:25 – 13:50
Antifungal prophylaxis – facing the challenges and obstacles – J. Maertens (Leuven, Belgium)
13:50 – 14:00
Wrap-up and questions – J.M. Aguado (Madrid, Spain)
25
List of Sponsors
AMGEN GmbH
Associates of Cape Cod
Astellas Pharma GmbH
Durata Therapeutics
Gilead Sciences GmbH
Merck & Co., Inc
Pfizer Pharma GmbH
Roche Diagnostics Deutschland GmbH
Roche Pharma AG
Vidara Therapeutics Inc
FSA-List
According to the principles of the FSA-Kodex, please find here a full list of the fin ancial involvement of
the FSA-Members.
2.800,00 €
Amgen GmbH
Basic Package: Booth Astellas Pharma GmbH
Package: Symposium, Booth, Advertisement
in the Final Program, Congress Bag 20.000,00 €
Gilead Sciences GmbH
Unrestricted educational grant, booth, Lanyards 10.000,00 €
Pfizer Pharma GmbH
Package: Symposium, Booth, Advertisement in the
Final Program, Pads & Pens 20.000,00 €
Roche Pharma AG
Basic Package: Booth 2.800,00 €
State by printing, please find a current list of the financial involvement of the FSA-Members at the
website www.ichs.org/Berlin -> Sponsorship & Exhibitions.
26
Something about Berlin
Brandenburg Gate
Museum Island
German Historic Museum
Photos: Berlin Partner / FTB-Werbefotografie; Habel Weinkultur
Cupola of the German Parliament
We offer you a warm welcome to Berlin, the capital of Germany and
one of the most exciting and inspiring cities of Europe. Considered
a cosmopolitan city, it is a pulsating center of politics, art, science,
culture and history. Therefore it is worth to visit for example one of
the grand museums of the Museum Island, the German Parliament
with its walkable cupola which offers a magnificent 360° view over
the city or the famous Brandenburg Gate – all in walking distance to
the congress venue.
Alexanderplatz with Television Tower
Charité
Right next to the historic Langenbeck-Virchow-Haus you will find
the Charité area, where you can take a look around the Berlin Museum of Medical History, arised from the pathological museum of
Rudolf Virchow. Also city of Robert Koch and Max Planck, Berlin is
the ideal place for such an important event as the 18th Symposium
on Infections in the Immunocompromised Host, to be held from 15
to 17 June 2014 in the heart of the city.
Potsdamer Platz
German Parliament
ICHS Social Event at Restaurant „Habel Weinkultur“
16 June 2014, 19:30 · Luisenstr. 19, 10117 Berlin
We are looking forward to welcoming you at the Restaurant Habel
for the ICHS Social Event 2014. Only a few footsteps away from the
Langenbeck-Virchow-Haus you will enjoy a lovely evening with a
delicious 3-course menu in a cosy atmosphere underneath the local
city railway in the heart of Berlin.
65,00 € p. P.
27
Getting to Berlin
City map of the key points
Getting to Berlin by car
From all directions, highways and national roads lead to Berlin. They all cross the highway which
encircles Berlin, known as the “Berliner Ring“. From there feeder roads, urban highways and exits
guide drivers towards the center of Berlin.
Please find more information about travelling by car here:
http://www.berlin.de/en/tourism/travel-information/1721197-2862820-arrival-in-berlin-by-car.en.html
28
Getting to Berlin by Rail or Airplane
Acting today for tomorrow: Travel by train from Euro 99 with 100 % green power
to 18th Symposium on Infections in the Immuno-compromised host
In cooperation with INTERPLAN Congress, Meeting & Event Management AG and Deutsche Bahn you
travel safely and and conveniently to 18th Symposium on Infections in the immunocompromised host!
Your way to save the environment: Travel with 100% green power to your event with Deutsche Bahn
long-distance services. We guarantee to get the energy you needed for your journey in Germany from
100% renewable sources.
The price for your Event Ticket for a return trip* to Berlin is:
• 2nd class Euro 99
• 1st class Euro 159
Our service centre is looking forward to inform you about the ticket price for international journeys.
Your ticket is valid from 13th to 19th June 2014.
In order to book call +49 (0)1806 - 31 11 53** and quote ”Interplan” as reference. Have your credit card
ready please.
From now on, every time you purchase an Event Ticket with your BahnCard or bahn.bonus Card you can
collect valuable bonus and status points. Redeem your bonus points by selecting attractive offers such as
free journeys or first-class upgrades. For more information go to www.bahn.de/bahn.bonus
Your price advantages compared to the regular prices***:
e. g. for your journey from
(return trip)
Munich
Frankfurt/M.
Cologne
Dusseldorf
Hamburg
<-->
<-->
<-->
<-->
<-->
Berlin
Berlin
Berlin
Berlin
Berlin
1st class – 159 €
Regular Fare
Your Price
Advantage
422 €
263 €
398 €
239 €
380 €
221 €
360 €
201 €
252 €
93 €
2nd class – 99 €
Regular Fare
Your Price
Advantage
260 €
161 €
246 €
147 €
234 €
135 €
222 €
123 €
156 €
57 €
INTERPLAN and Deutsche Bahn wish you a pleasant journey!
*
** ***
An advance booking of at least three days is required. Changes and reimbursement before the first day of validity are possible. Changes and reimbursement conditions at the time
of the ticket booking are according to Conditions of Carriage of the DB of Sparpreis fares. Changes and reimbursement are excluded from the first day of validity onwards.
Passengers restrict themselves to a particular train and travel times. For a supplement of Euro 40 full flexible tickets are also available for domestic travels within Germany.
The booking line is available from Monday to Saturday 07:00 am to 10:00 pm. Calls will be charged at Euro 0.20 per call, from mobiles Euro 0.60 per call at maximum.
Prices are subject to change.
Special offer with Lufthansa
Lufthansa German Airlines offers a comprehensive global route network
linking Berlin with major cities around the world.
Participants of the 18th Symposium on Infections in the Immunocompromised Host and their travel
companions benefit from special fares and conditions in First, Business and Economy class. To make your
reservation, please click on this link: www.lufthansa.com/event-booking_en
This will lead you to an online booking platform that will automatically calculate your discount.
Note: Pop-ups must be enabled. Otherwise the booking platform window will not open!
The booking code for this congress is: DEZAQPX
For more and detailed information about the conference, please visit the website www.ichs.org.
It will be a great pleasure for us to welcome you at the ICHS-Conference in Berlin.
29
Floor Plan
Company
Booth
AMGEN GmbH
7
Associates of Cape Cod
8
Astellas Pharma GmbH
1
Gilead Sciences GmbH
4
Merck & Co., Inc
5
Pfizer Pharma GmbH
2
Roche Diagnostics
Deutschland GmbH
3
Roche Pharma AG
6
7
8
6
5
3
4
2
1
DIFICLIRTM 200 mg Filmtabletten. Wirkstoff: Fidaxomicin. Zusammensetzung: 1 Tablette enthält 200 mg Fidaxomicin. Sonstige Bestandteile: Tablettenkern: Mikrokristalline Cellulose,
vorverkleisterte Stärke, Hydroxypropylcellulose, butyliertes Hydroxytoluol, Carboxymethylstärke-Natrium, Magnesiumstearat. Umhüllung: Polyvinylalkohol, Titandioxid, Talkum, Macrogol,
Lecithin (Soja). Anwendungsgebiete: DIFICLIR™ ist indiziert bei Erwachsenen zur Behandlung von Clostridium-difficile-Infektionen (CDI), auch bekannt unter der Bezeichnung Clostridiumdifficile-assoziierte Diarrhö (CDAD). Offizielle Leitlinien zum angemessenen Gebrauch von Antibiotika sollten berücksichtigt werden. Gegenanzeigen: Überempfindlichkeit gegen den
Wirkstoff oder einen der sonstigen Bestandteile. Nebenwirkungen: Häufig (1 – 10 %): Hautausschlag, Juckreiz, Erbrechen, Übelkeit, Obstipation. Gelegentlich (0,1 – 1 %): Appetitabnahme,
Schwindelgefühl, Kopfschmerzen, Geschmacksstörungen, Völlegefühl, Flatulenz, Mundtrockenheit, Anstieg der Alanin-Aminotransferase. Häufigkeit auf Grundlage der verfügbaren Daten
nicht abschätzbar: Überempfindlichkeitsreaktionen (Angioödeme, Dyspnoe). Warnhinweise: Siehe Fachinformation. Weitere Einzelheiten und Hinweise: Siehe Fach- und Gebrauchsinformation. Verschreibungspflichtig. Stand der Information: August 2013. Astellas Pharma GmbH, Postfach 50 01 66, 80971 München.
MYCAMINE® 50 mg Pulver zur Herstellung einer Infusionslösung, MYCAMINE® 100 mg Pulver zur Herstellung einer Infusionslösung. Wirkstoff: Micafungin (als NatriumSalz). Zusammensetzung: 1 Durchstechflasche enthält Wirkstoff: 50 mg bzw. 100 mg Micafungin als Natrium-Salz. Nach Rekonstitution enthält jeder Milliliter 10 mg bzw. 20 mg
Micafungin als Natrium-Salz. Sonstige Bestandteile: Lactose-Monohydrat, Citronensäure (zur Einstellung des pH-Werts), Natriumhydroxid (zur Einstellung des pH-Werts).
Anwendungsgebiete: MYCAMINE® ist indiziert bei Erwachsenen, Jugendlichen ≥ 16 Jahre und älteren Patienten zur: Behandlung einer invasiven Candidose; Behandlung der ösophagealen
Candidose bei Patienten, für die eine intravenöse Behandlung angebracht ist; Prophylaxe von Candida-Infektionen bei Patienten, die sich einer allogenen, hämatopoetischen Stammzelltransplantation unterziehen oder wenn eine Neutropenie (absolute Neutrophilenzahl < 500 Zellen/µl) von mindestens 10 oder mehr Tagen zu erwarten ist. MYCAMINE® ist indiziert bei
Kindern (einschließlich Neugeborener) und Jugendlichen < 16 Jahre zur: Behandlung einer invasiven Candidose; Prophylaxe von Candida-Infektionen bei Patienten, die sich einer allogenen,
hämatopoetischen Stammzelltransplantation unterziehen oder wenn eine Neutropenie (absolute Neutrophilenzahl < 500 Zellen/µl) von mindestens 10 oder mehr Tagen zu erwarten ist.
Die Entscheidung, MYCAMINE® anzuwenden, sollte in Betracht ziehen, dass ein mögliches Risiko zur Lebertumorbildung besteht. MYCAMINE® ist daher nur anzuwenden, wenn andere
Antimykotika nicht angemessen sind. Gegenanzeigen: Überempfindlichkeit gegen den Wirkstoff, gegen andere Echinocandine oder einen der sonstigen Bestandteile. Nebenwirkung:
Häufig (≥ 1/100 bis < 1/10): Leukopenie, Neutropenie, Anämie; Hypokaliämie, Hypomagnesiämie, Hypokalziämie; Kopfschmerzen; Phlebitis; Übelkeit, Erbrechen, Diarrhö, Bauchschmerzen; erhöhte alkalische Phosphatase im Blut, erhöhte Aspartataminotransferase, erhöhte Alaninaminotransferase, erhöhtes Bilirubin im Blut (einschließlich Hyperbilirubinämie), abnormer
Leberfunktionstest; Hautausschlag; Fieber, Rigor. Gelegentlich (≥ 1/1.000 bis < 1/100): Panzytopenie, Thrombozytopenie, Eosinophilie, Hypoalbuminämie; anaphylaktische/ anaphylaktoide Reaktionen, Überempfindlichkeit; Hyperhidrose; Hyponatriämie, Hyperkaliämie, Hypophosphatämie, Anorexie; Schlaflosigkeit, Ängstlichkeit, Verwirrtheit; Somnolenz, Zittern, Schwindel,
Geschmacksstörungen; Tachykardie, Palpitationen, Bradykardie; Hypotonie, Hypertonie, Flush; Dyspnoe; Dyspepsie, Obstipation; Leberversagen, erhöhte Gammaglutamyltransferase,
Ikterus, Cholestase, Hepatomegalie, Hepatitis; Urtikaria, Pruritus, Erythem; erhöhtes Kreatinin im Blut, erhöhter Harnstoff im Blut, Verschlimmerung eines Nierenversagens; Thrombose
an der Einstichstelle, Entzündung im Infusionsbereich und Schmerzen an der Einstichstelle, peripheres Ödem; erhöhte Lactatdehydrogenase im Blut. Selten (≥ 1/10.000 bis < 1/1.000):
hämolytische Anämie, Hämolyse. Nicht bekannt (Häufigkeit auf Grundlage der verfügbaren Daten nicht abschätzbar): disseminierte intravasale Gerinnung; Schock; hepatozelluläre Schädigung, einschließlich Todesfällen; toxischer Hautausschlag, Erythema multiforme, Stevens-Johnson-Syndrom, toxische epidermale Nekrolyse; Nierenfunktionsstörung, akutes Nierenversagen.
Bei Kindern kamen einige der unerwünschten Nebenwirkungen häufiger vor als bei Erwachsenen: Häufig (≥ 1/100 bis < 1/10): Thrombozytopenie; Tachykardie; Hypertonie, Hypotonie;
Hyperbilirubinämie, Hepatomegalie; akutes Nierenversagen, Harnstoff im Blut erhöht. Kinder < 1 Jahr zeigten ca. zweimal häufiger einen Anstieg in ALT, AST und AP als ältere Kinder.
Warnhinweis: Hepatische Wirkungen: Nach einer Behandlungsperiode von ≥ 3 Monaten wurden bei Ratten Herde histologisch alterierter Hepatozyten (FAH, foci of altered hepatocytes)
und hepatozelluläre Tumoren beobachtet. Der vermutliche Schwellenwert für die Tumorentwicklung bei Ratten befand sich in etwa im Bereich der klinischen Exposition. Es kann nicht
ausgeschlossen werden, dass dieser Befund von Relevanz für die therapeutische Anwendung ist. Während der Behandlung mit Micafungin muss die Leberfunktion sorgfältig kontrolliert
werden. Frühzeitiges Absetzen von MYCAMINE® wird empfohlen, wenn die ALT-/AST-Werte signifikant und dauerhaft erhöht sind, um das Risiko einer adaptiven Regenerierung und einer
eventuellen anschließenden Bildung von Lebertumoren zu minimieren. Eine Behandlung mit Micafungin sollte auf Basis einer sorgfältigen Nutzen-Risiko-Bewertung erfolgen, insbesondere bei Patienten mit schwerer Leberinsuffizienz oder chronischen Lebererkrankungen, die bekanntermaßen präneoplastische Prozesse darstellen, wie fortgeschrittene Leberfibrose,
Zirrhose, Virushepatitis, Lebererkrankung bei Neugeborenen oder kongenitale Enzymdefekte, oder bei Patienten, die eine Begleittherapie erhalten, insbesondere mit hepatotoxischen und/
oder genotoxischen Eigenschaften. Verschreibungspflichtig. Weitere Einzelheiten enthalten Fach- und Gebrauchsinformation.
Pharmazeutischer Unternehmer: Astellas Pharma Europe B.V., Sylviusweg 62, 2333 BE Leiden, Niederlande. Deutsche Vertretung
des pharmazeutischen Unternehmers: Astellas Pharma GmbH, Postfach 50 01 66, 80971 München. Stand: Dezember 2013.
A N T I I N F E K T I VA
30
A N T I I N F E K T I VA
Über 1.000.000 Patienten* –
weltweite Erfahrung
Selektiv. Bakterizid. Anhaltend wirksam.# 1,2
Bei C.difficile-Infektionen
* Quotient aus Substanz in kg (Quelle: IMS Midas Substanz in kg – 12/02 bis 09/12) und durchschnittlicher Tagesdosis
über 14 Tage. (Quelle: Fachinformationen Cancidas®, Ecalta®, Mycamine®, Stand Januar 2013).
#
Im Vergleich zu Vancomycin signifikant höhere Raten anhaltender Heilung, definiert als Abklingen der Diarrhö unter der
Therapie, und kein Rezidiv innerhalb von 30 Tagen nach Beendigung der Therapie.
1. Louie TJ et al. N Engl J Med 2011; 364(5): 422 – 431.
2. Cornely OA et al. Lancet Infect Dis 2012; 12: 281 – 289.
31
Welcome to the ICHS14 in Berlin
MSD IS COMMITTED
TO HELP FIGHT
INFECTIOUS DISEASES.
Before prescribing CANCIDAS or NOXAFIL, please read the Prescribing Information
available at this exhibit or at www.ema.europa.eu
Please visit us at
Booth #5
32
Copyright © 2014 Merck Sharp & Dohme Corp.,
a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA.
All rights reserved. AINF-1069768-0002 04/14